Applied Molecular Evolution (NASDAQ:AMEV)
Historical Stock Chart
From Jun 2019 to Jun 2024
AME Sets January 5, 2004 as Record Date for Stockholder Meeting to Vote on
Proposed Merger
SAN DIEGO, Jan. 2 /PRNewswire-FirstCall/ -- Applied Molecular Evolution, Inc.
today announced that it has established a record date for its special
stockholder meeting to vote on the previously announced proposed merger of
Genesis Merger Sub, Inc., a wholly owned subsidiary of Eli Lilly and Company ,
into AME, pursuant to which AME would become a wholly owned subsidiary of Lilly.
AME stockholders of record at the close of business on Monday, January 5, 2004
will be entitled to notice of the special meeting and to vote on the proposed
merger.
AME will send a definitive proxy statement/prospectus to holders of AME common
stock as of the record date. The definitive proxy statement/prospectus will
contain important information about the proposed merger, including the date,
time and location of the special meeting of AME stockholders. AME stockholders
are urged to read the definitive proxy statement/prospectus when it becomes
available.
About AME
Applied Molecular Evolution, Inc. (AME) is a leader in applying directed
molecular evolution to improve healthcare by optimizing and developing human
biotherapeutics. Directed molecular evolution is a process for optimizing genes
and proteins for specific commercial purposes. Since its inception, AME's
principal focus has been on applying its proprietary AMEsystem(TM) technology
platform to human biotherapeutics, the largest market for directed molecular
evolution. Biotherapeutics, or biopharmaceuticals, are protein pharmaceuticals
such as antibodies, cytokines, hormones and enzymes. AME uses its proprietary
technology to develop improved versions of currently marketed, FDA-approved
biopharmaceuticals as well as novel human biotherapeutics. For more
information, please visit the Internet website located at http://www.ame.biz/ .
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Indiana, Lilly provides answers -- through medicines and
information - for some of the world's most urgent medical needs. Additional
information about Lilly is available at the Internet website located at
http://www.lilly.com/ .
Forward Looking Statements
This press release contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results to differ materially from
those set forth in the forward looking statements, including if the acquisition
will be approved by AME's stockholders, if the acquisition will obtain
regulatory approval under the Hart-Scott-Rodino Antitrust Improvements Act and
other regulatory approvals, whether the waiting periods for such approvals will
be extended due to requests for additional information, whether AME will
successfully complete the transaction and those matters set forth, or
incorporated by reference, in the risk factor section of Lilly's Registration
Statement on Form S-4 filed with the Securities and Exchange Commission on
December 22, 2003. These forward looking statements represent AME's judgment as
of the date of this press release. AME disclaims any intent or obligation to
update these forward looking statements.
Additional Information About the Merger and Where to Find It
This press release is for informational purposes only and is not an offer to buy
or the solicitation of an offer to sell any Lilly shares, and is not a
solicitation of a proxy. In connection with the proposed merger of a wholly
owned subsidiary of Lilly with and into AME, Lilly and AME filed a preliminary
proxy statement/prospectus with the Commission on December 22, 2003, as part of
a Registration Statement on Form S-4. Once the Registration Statement is
declared effective by the Commission, the definitive proxy statement/prospectus
will be sent to AME stockholders in connection with the solicitation of their
approval of the proposed merger. Also, you may obtain a free copy of the
Registration Statement, as well as other documents filed by Lilly and AME with
the Commission, at the Commission's Internet website located at
http://www.sec.gov/ . Investors and security holders are advised to read the
definitive proxy statement/prospectus and the Registration Statement in their
entirety because important information will be contained therein. Once declared
effective by the Commission, the Registration Statement also will be available
from Lilly by contacting Eli Lilly and Company, Lilly Corporate Center,
Indianapolis, Indiana 46285, Attention: Shareholder Services (317) 276-6993 and
from AME by contacting Applied Molecular Evolution, Inc., 3520 Dunhill Street,
San Diego, California 92121, Attention: Investor Relations (858) 597-4990.
Lilly, AME and their respective directors and executive officers may be deemed
to be participants in the solicitation of proxies from AME stockholders in
connection with the merger. Information about the directors and executive
officers of AME and their interests in the merger, including their ownership of
AME stock, is set forth in the proxy statement for the 2003 annual meeting of
AME stockholders. Information about the directors and executive officers of
Lilly and their interests in the merger, including their ownership of Lilly
stock, is set forth in the proxy statement for the 2003 annual meeting of Lilly
shareholders. Investors may obtain additional information regarding the
interests of such participants in the merger by reading the definitive proxy
statement/prospectus when it becomes available.
For further information, please contact Christopher Erdman of Applied Molecular
Evolution, +1-858-638-8635.
DATASOURCE: Applied Molecular Evolution, Inc.
CONTACT: Christopher Erdman of Applied Molecular Evolution,
+1-858-638-8635
Web site: http://www.lilly.com/
http://www.ame.biz/